CAMBRIDGE, Mass., Nov. 2, 2015 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com) announces the kick-off of the 2015-2016 QSP-SB Industry & Academia Symposium series. This week, top pharma and biotech representatives will meet along with local faculty, students, and post docs, for the Fall QSP-SB Industry & Academia Symposium. This Symposium:
Dr. John Burke, Co-Founder, President, and CEO of Applied BioMath, realized that such an industry-academic collaboration and networking opportunity was lacking in the QSP and SB community. He had benefited from and enjoyed a similar type of event hosted by the Cell Decision Process (CDP) Center (http://www.cdpcenter.org) during his post-doc work at MIT and HMS. With strong academic enthusiasm from thought leaders such as Douglas Lauffenburger and Peter Sorger, Dr. Burke and Applied BioMath initiated the QSP-SB Industry & Academia symposium series, modeled closely after the CDP meetings, and held the inaugural symposium last spring. Overwhelming industry response is more than doubling this year's attendees.
"As a company with both CEO and CSO having done their post-doc and PhD at MIT respectively, and seeing how the CDP strengthened science and community, I am very excited by the potential of growing this community, to support each other, meet the future modelers, and hear from thought leaders in industry and academia." – John M. Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
Each symposium is typically comprised of two presentations from pharma and biotech researchers, along with networking opportunities. The Fall QSP-SB Industry & Academia symposium will feature Anne Heatherington, PhD, Vice President, Head of Quantitative Clinical Sciences at a leading pharmaceutical company, and Kevin Dykstra, PhD, President/CEO of qPharmetra.
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), helps biotech and pharmaceutical companies reduce late stage attrition and accelerate best-in-class (BIC) drugs using quantitative methodologies. Leveraging biology, high performance computing (HPC), proprietary technology and experience in pharma, Applied BioMath delivers biological insights proven to shorten project timelines, lower costs, and develop BIC drugs. Services include knowledge gap analysis, experiment prioritization and design, BIC drug property and tox predictions, indication and patient selection, and optimal clinical trial design and analysis.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
Logo - http://photos.prnewswire.com/prnh/20150915/266672LOGO
SOURCE Applied BioMath